کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6258598 | 1612973 | 2014 | 9 صفحه PDF | دانلود رایگان |
- Systemic administration of LP-211 increases wakefulness and reduces REM sleep.
- Microinjection of LP-211 into the DRN, LC, BFB or LDT suppresses REM sleep.
- Similar changes were described after administration of other 5-HT receptor agonists.
The effects of LP-211, a selective serotonin 5-HT7 receptor agonist were studied in adult rats implanted for chronic sleep recordings. Intraperitoneal administration of LP-211 (2.5-10Â mg/kg) during the light phase of the light-dark cycle significantly increased wakefulness (W) and reduced rapid-eye-movement sleep (REMS) and the number of REM periods during the 6-h recording period. Direct infusion of LP-211 into the dorsal raphe nucleus (DRN) (2-6Â mM), locus coeruleus nucleus (LC) (4Â mM), basal forebrain (horizontal limb of the diagonal band of Broca) (HDB) (2Â mM) or laterodorsal tegmental nucleus (LDT) (4Â mM) induced also a decrease of REMS. Additionally, microinjection of the 5-HT7 receptor ligand into the HDB (2Â mM) augmented W. Presently, there is no satisfactory explanation for the effect of 5-HT7 receptor activation on W and REMS occurrence. Additional studies are required to characterize the neurotransmitter systems responsible for the actions of LP-211 on the behavioral states.
Journal: Behavioural Brain Research - Volume 259, 1 February 2014, Pages 321-329